Olga Oestrup

Copenhagen Prospective Personalized Oncology (CoPPO)—Clinical Utility of Using Molecular Profiling to Select Patients to Phase I Trials

Ida Viller Tuxen, Kristoffer Staal Rohrberg, Olga Oestrup et al. · Clinical Cancer Research · 2018 · 95 citations

Medicine, Molecular Medicine, Oncology +17

High frequency of pathogenic germline variants within homologous recombination repair in patients with advanced cancer

Birgitte Bertelsen, Ida Viller Tuxen, Christina W. Yde et al. · npj Genomic Medicine · 2019 · 82 citations · Full text

Life Sciences, Genetics, Oncology +15

Epigenetic regulation of gene expression in porcine epiblast, hypoblast, trophectoderm and epiblast-derived neural progenitor cells

Yu Gao, Hélène Jammes, Mikkel A. Rasmussen et al. · Epigenetics · 2011 · 26 citations · Full text

Life Sciences, Developmental Biology, Molecular Biology +17

Circulating tumor DNA as a marker of treatment response in BRAF V600E mutated non-melanoma solid tumors

Lise Barlebo Ahlborn, Ida Viller Tuxen, Florent Moulière et al. · Oncotarget · 2018 · 16 citations · Full text

Medicine, Molecular Genetics, Oncology +17

Plasma total cell-free DNA is a prognostic biomarker of overall survival in metastatic solid tumour patients

Ida Viller Tuxen, Lise Barlebo Ahlborn, Morten Mau‐Sørensen et al. · British Journal of Cancer · 2019 · 13 citations · Full text

Medicine, Clinical Sciences, Oncology +17